Ischemic Reperfusion Articles & Analysis
4 news found
The disease that Villix first targeted is ischemic reperfusion injury that occurs in organ transplant myocardial infarction, coronary artery bypass surgery, and stroke. ...
Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water. It is Bilix that solved this problem. ...
Currently, the primary challenge ahead is the development of treatments for ischemic reperfusion injury (IRI). To date, there are no drugs approved for the treatment of IRI. ...
The disease that Bilix has targeted is ischemic reperfusion injury caused by organ transplantation, myocardial infarction, coronary artery bypass grafting, and stroke. ...